Learning Library
Find all published Papers, Posters, and Abstracts
Featured
From Diagnostic Uncertainty to Whole-System Efficiency
Sepsis and severe infections place strain on emergency departments and inpatient capacity. Overcrowding, prolonged boarding, and resource strain create downstream operational and financial pressure.
Papers, Posters, and Abstracts
Videos and Webinars
From Uncertainty to Clarity: Transforming Emergency Department Infection Diagnosis with Host Response Technology
Watch the video
FAQs
MeMed BV measures three key immune response biomarkers:
- TRAIL (TNF-Related Apoptosis-Inducing Ligand): The first FDA-cleared biomarker that rises with viral infections and decreases in bacterial infections.
- IP-10 (Interferon Gamma-Induced Protein 10): A chemokine involved in immune cell activation and chemotaxis. Altered expression is linked to inflammation, infection, and immune dysregulation.
- CRP (C-Reactive Protein): A well-known acute-phase protein that rises in both bacterial and viral infections, depending on the time since symptom onset.
A machine learning–derived algorithm combines these values into a single score that helps distinguish bacterial vs. viral infections within 7 days of symptom onset.
Yes. MeMed BV has a PLA CPT code 0315U. Consult CodeMap for additional details.
- LIAISON® MeMed BV requires a serum sample.
- MeMed Key accepts either serum or whole blood (whole blood option is FDA-cleared in the U.S.).
In the U.S.: For patients in ED or urgent care with suspected acute bacterial or viral infections, especially those with fever and symptoms ≤7 days.
Recommended Uses:
- Antibiotic cessation in ICU patients
- Lower respiratory tract infections (e.g., CAP, AECOPD)
- Neonates over 34 weeks gestation, with caution in preterms
Not Recommended For:
- Initiation of antibiotics
- Mortality prediction in sepsis (despite FDA clearance)
In summary:
Not recommended in the ED for diagnosis or treatment initiation.
Best used in ICU or hospitalized patients for guiding antibiotic discontinuation.
Yes. MeMed BV can identify bacterial immune responses even in the presence of viral co-infections, providing clearer guidance for treatment decisions.
The score reflects the likelihood of bacterial vs. viral infection, not disease severity.
Yes. MeMed BV is pathogen-agnostic, analyzing the host immune response instead of targeting specific pathogens. This makes it useful even for novel or unknown infectious agents.